title: Irreversible corneal decompensation in patients treated with topical dorzolamide.
abstract: OBJECTIVE
  To describe irreversible corneal decompensation after topical dorzolamide hydrochloride (Trusopt; Merck and Co, Inc, West Point, Pennsylvania) therapy in nine patients who had histories consistent with corneal endothelial compromise.
  
  
  METHODS
  Multicenter review of patients' charts.
  
  
  RESULTS
  Nine eyes of nine patients developed overt corneal decompensation after starting topical dorzolamide, a condition that did not resolve with drug cessation. This occurred after 3 to 20 weeks (mean, 7.8) of therapy. All nine patients had undergone intraocular surgery. Eight patients had undergone cataract surgery; three were aphakic and three had posterior chamber intraocular lenses. Two patients had anterior chamber intraocular lenses and also had undergone trabeculectomies. Four patients had undergone penetrating keratoplasties, each case complicated by episodes of corneal allograft rejection that were successfully treated. Two patients had asymptomatic Fuchs endothelial dystrophy. Seven patients have since undergone successful penetrating keratoplasties.
  
  
  CONCLUSIONS
  The reports suggest that dorzolamide can cause irreversible corneal edema in a subset of glaucoma patients with endothelial compromise. The findings suggest a rationale for research into the long-term effects of dorzolamide on the corneal endothelium.
authors.affiliation: Department of Ophthalmology, Rush Presbyterian-St Luke's Medical Center, Chicago, Illinois 60012, USA.
authors.forename: A
authors.initials: A
authors.lastname: Konowal
authors.forename: J C
authors.initials: JC
authors.lastname: Morrison
authors.forename: S V
authors.initials: SV
authors.lastname: Brown
authors.forename: D L
authors.initials: DL
authors.lastname: Cooke
authors.forename: L J
authors.initials: LJ
authors.lastname: Maguire
authors.forename: D V
authors.initials: DV
authors.lastname: Verdier
authors.forename: F T
authors.initials: FT
authors.lastname: Fraunfelder
authors.forename: R F
authors.initials: RF
authors.lastname: Dennis
authors.forename: R J
authors.initials: RJ
authors.lastname: Epstein
mesh_terms: D000287:Administration, Topical; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002257:Carbonic Anhydrase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D015715:Corneal Edema / Q000139:chemically induced* / Q000473:pathology; D004728:Endothelium, Corneal / Q000187:drug effects* / Q000473:pathology; D005260:Female; D005901:Glaucoma / Q000188:drug therapy; D006801:Humans; D007429:Intraocular Pressure; D015948:Keratoplasty, Penetrating; D008297:Male; D008875:Middle Aged; D009883:Ophthalmic Solutions / Q000009:adverse effects / Q000627:therapeutic use; D012030:Refractive Errors / Q000139:chemically induced* / Q000473:pathology; D012189:Retrospective Studies; D013449:Sulfonamides / Q000009:adverse effects* / Q000627:therapeutic use; D013876:Thiophenes / Q000009:adverse effects* / Q000627:therapeutic use; D014792:Visual Acuity
chemical_list: D002257:Carbonic Anhydrase Inhibitors; D009883:Ophthalmic Solutions; D013449:Sulfonamides; D013876:Thiophenes; C062765:dorzolamide